GlobeNewswire·Nov 12, 2026, 4:01 PM ET

Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

Heartflow, Inc. reported total revenue of $72.9 million for the third quarter ended September 30, 2026, representing a 57% year-over-year increase.
U.S. revenue reached $67.9 million, a 60% year-over-year increase, while international revenue was $4.9 million, a 29% increase.
The company reported a gross margin of 83.6% (non-GAAP: 83.8%) compared to 76.5% in the prior year period.
Net operating loss was $13.8 million, with a non-GAAP net operating loss of $5.0 million.
Net loss for the quarter was $11.5 million, or $0.13 per share, compared to a net loss of $50.9 million, or $1.04 per share, in the prior year.
Adjusted EBITDA for the quarter was a loss of $3.6 million, an improvement from a loss of $9.8 million in the prior year.
Heartflow raised its 2026 annual revenue guidance to $262 million to $264 million, reflecting approximately 49% to 50% year-over-year growth.
The 2026 non-GAAP gross margin guidance was increased to approximately 82.5% from a previous estimate of 82%.
Cash, cash equivalents, and investments totaled $253.0 million as of September 30, 2026.
Revenue growth was driven by increased U.S. FFR CT case volume, higher U.S. Plaque revenue case volume, and rapid expansion of the installed base.
Operating expenses increased to $74.8 million due to investments in sales personnel, technology, and clinical research.
The company highlighted that Heartflow Plaque Analysis activations are ramping ahead of plan with broadening utilization across CCTA procedures.